Welcome to our dedicated page for Talphera SEC filings (Ticker: TLPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Talphera, Inc. filings document the regulatory record for a Nasdaq-listed specialty pharmaceutical company focused on medically supervised therapies. Recent Form 8-K reports cover financial results, corporate updates, private placements of common stock and pre-funded warrants, board appointments, equity-plan matters and Nasdaq listing-compliance notices.
The company’s proxy materials describe stockholder voting matters, director elections, executive compensation, equity awards and employee stock plan approvals. Talphera’s filings also identify its Delaware incorporation, Nasdaq Capital Market listing, registered common stock and capital-structure disclosures relevant to its pharmaceutical development business.
TALPHERA, INC. director Mark A. Wan reported equity awards that increase his direct stake in the company. He received 5,100 shares of common stock as a grant, bringing his direct holdings to 13,959 shares. He was also granted options to buy 30,700 shares of common stock at an exercise price of $0.98 per share, expiring on June 21, 2036. The filing notes that the 5,100 restricted stock units and all of the option shares vest in full on the first anniversary of the grant date, as long as he continues to provide service to TALPHERA.
TALPHERA, INC. director Joseph Todisco reported equity awards under the company’s compensation program. He acquired 5,100 shares of common stock at no cost, bringing his direct holdings to 11,497 shares after the transaction.
He was also granted a director stock option covering 30,700 shares of common stock at an exercise price of $0.98 per share, expiring on June 21, 2036. According to the footnotes, 100% of these stock units and option shares vest on the first anniversary of the June 22, 2026 grant date, subject to his continuous service to the company.
TALPHERA, INC. director Abhinav Jain reported equity compensation grants consisting of restricted stock units and stock options. He received 5,100 shares of common stock as a grant, bringing his direct holdings to 12,412 shares after the transaction. These awards carry no cash purchase price.
On the same date, he was granted stock options for 30,700 shares of common stock at an exercise price of $0.98 per share, expiring on June 21, 2036. Footnotes state that 100% of the restricted stock units and 100% of the option shares vest on the first anniversary of the grant date, subject to his continuous service to the company.
TALPHERA, INC. director Stephen J. Hoffman received new equity awards as part of his compensation. On June 22, 2026, he was granted 5,100 shares of common stock at no cost, increasing his direct common stock holdings to 13,959 shares after the award.
He also received a stock option for 30,700 shares of common stock with an exercise price of $0.98 per share, expiring on June 21, 2036. Footnotes state that all 5,100 restricted stock units and all 30,700 option shares will vest in full on the first anniversary of the grant date, provided he continues to serve the company.
TALPHERA, INC. director Jill Marie Broadfoot reported equity awards consisting of restricted stock units and stock options. She received 5,100 shares of common stock as a grant at no cost and now holds 13,647 common shares directly. She was also granted options on 30,700 shares at an exercise price of $0.98 per share, expiring in 2036. Both the restricted stock units and the option grant vest in full on the first anniversary of the grant date, contingent on her continuous service with the company.
TALPHERA, INC. director Marina Bozilenko received equity compensation in the form of restricted stock units and stock options. She was granted 5,100 restricted stock units, each representing one share of common stock, all vesting on the first anniversary of the grant date, subject to her continuous service.
She was also granted options to purchase 30,700 shares of common stock at an exercise price of $0.98 per share, with 100% of the option shares vesting on the one-year anniversary of the grant date, also contingent on continued service. Following these awards, she directly holds 14,147 shares of common stock and 30,700 options.
TALPHERA, INC. director Adrian Adams received new equity awards. On June 22, 2026, he was granted 5,100 restricted stock units, each representing the right to receive one share of common stock. These RSUs vest 100% on the first anniversary of the grant, if he remains in continuous service.
Adams also received a stock option for 30,700 shares of common stock at an exercise price of $0.98 per share, expiring on June 21, 2036. The option vests in full one year after the grant date, subject to his continued service, and brings his direct common stock holdings to 22,709 shares after the RSU grant.
Talphera, Inc. held its 2026 Annual Meeting of Stockholders on June 22, 2026, where shareholders voted on directors, auditor ratification, executive pay and equity plans. Three Class III directors — Marina Bozilenko, Joseph Todisco and Mark Wan — were elected to serve until the 2029 Annual Meeting.
Shareholders ratified BPM LLP as independent auditor for the year ending December 31, 2026 and approved, on an advisory basis, the compensation of named executive officers. They also approved amended and restated versions of Talphera’s 2020 Equity Incentive Plan and 2011 Employee Stock Purchase Plan, which provide the main stock-based compensation frameworks for employees and executives.
TALPHERA, INC. Chief Medical Officer Shakil Aslam reported a routine tax-related share disposition. On May 20, 2026, 4,518 shares of common stock were surrendered to the company to cover required tax withholdings tied to the vesting of restricted stock units. After this non-market transaction, Aslam directly holds 76,542 shares of TALPHERA common stock.
Talphera, Inc. filed Amendment No. 2 to a Schedule 13G/A reporting that Laurence W. Lytton and the Lytton-Kambara Foundation each beneficially own 1,246,444 shares of Common Stock. The filing states this equals 2.5% of the class, calculated from 50,049,824 shares outstanding as of March 18, 2026.
The report breaks out voting and dispositive power as 0 sole and 1,246,444 shared for both reporting persons and includes an agreement regarding a joint filing as Exhibit 99.1.